Effect of dimethyl fumarate on renal disease progression in a genetic ortholog of nephronophthisis

Dimethyl Fumarate Controls the NRF2/DJ-1 Axis in Cancer Cells: Therapeutic Applications

(2017) Nathaniel Edward Bennett Saidu et al.   MOLECULAR CANCER THERAPEUTICS

Resveratrol Supplementation and Oxidative/Anti-Oxidative Status in Patients with Ulcerative Colitis: A Randomized, Double-Blind, Placebo-controlled Pilot Study

(2016) Maryam Samsamikor et al.   ARCHIVES OF MEDICAL RESEARCH

Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm® - and placebo-controlled trial (BRIDGE)

(2016) U. Mrowietz et al.   BRITISH JOURNAL OF DERMATOLOGY

Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor κB-induced inflammation

(2016) Ming Wu et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease

(2016) Michelle H. T. Ta et al.   PLoS One

Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription

(2016) Eri H. Kobayashi et al.   Nature Communications

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up

(2016) Carrie M. Hersh et al.   Multiple Sclerosis and Related Disorders

Dimethyl Fumarate Reduces Inflammatory Responses in Experimental Colitis

(2015) Giovanna Casili et al.   Journal of Crohns & Colitis

Nephronophthisis: should we target cysts or fibrosis?

(2015) Gisela G. Slaats et al.   PEDIATRIC NEPHROLOGY

Treatment With Dimethyl Fumarate Attenuates Calcineurin Inhibitor-induced Nephrotoxicity

(2015) Chie Takasu et al.   TRANSPLANTATION

Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview

(2015) Roberto Bomprezzi   Therapeutic Advances in Neurological Disorders

Dimethyl Fumarate and Monoethyl Fumarate Exhibit Differential Effects on KEAP1, NRF2 Activation, and Glutathione Depletion In Vitro

(2015) Melanie S. Brennan et al.   PLoS One

Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)

(2014) Ralf Gold et al.   Multiple Sclerosis Journal

Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease

(2014) Robert W. Schrier et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activation of Nrf2 by dimethyl fumarate improves vascular calcification

(2014) Chae-Myeong Ha et al.   VASCULAR PHARMACOLOGY

Sirolimus ameliorates inflammatory responses by switching the regulatory T/T helper type 17 profile in murine colitis

(2013) Hui Yin et al.   IMMUNOLOGY

A Randomized Trial of Dietary Sodium Restriction in CKD

(2013) E. J. McMahon et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Macrophages promote polycystic kidney disease progression

(2013) Katherine I Swenson-Fields et al.   KIDNEY INTERNATIONAL

Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial

(2013) Anna Caroli et al.   LANCET

Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing–remitting multiple sclerosis: findings from the CONFIRM study

(2013) Mariko Kita et al.   Multiple Sclerosis Journal

Role of interstitial inflammation in the pathogenesis of polycystic kidney disease

(2013) Michelle HT Ta et al.   NEPHROLOGY

Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy

(2013) Mohammad A. Aminzadeh et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

A novel mutation causing nephronophthisis in the Lewis polycystic kidney rat localises to a conserved RCC1 domain in Nek8

(2012) John K McCooke et al.   BMC GENOMICS

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

(2012) Vicente E. Torres et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution

(2011) Keiko Taguchi et al.   GENES TO CELLS

Macrophages Promote Cyst Growth in Polycystic Kidney Disease

(2011) A. Karihaloo et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Water Prescription in Autosomal Dominant Polycystic Kidney Disease: A Pilot Study

(2010) C. J. Wang et al.   Clinical Journal of the American Society of Nephrology

mTOR Inhibitors in Polycystic Kidney Disease

(2010) Terry Watnick et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease

(2010) Andreas L. Serra et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nephronophthisis: Disease Mechanisms of a Ciliopathy

(2009) F. Hildebrandt et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY